Return to The AAPP Perspective issue main page.< Previous Article  Next Article >

Kristen N. Gardner, PharmD, BCPP; Clinical Pharmacy Specialist – Behavioral Health; Kaiser Permanente Colorado; CPNP Programming Committee Member

The first full day of programming at CPNP 2018 starts off with an all-star line-up, with a second keynote address for Monday, April 23. This session will review recognition and management of mixed depression from world renowned expert, Dr. Michael Thase.

While the current DSM-5 manual includes a new specifier for mixed features, there are no Food and Drug Administration approved medications to treat major depressive disorder with mixed features. There are only two guidelines that provide decision support to providers managing patients with depression with mixed features. Importantly, these guidelines differ in their recommendations namely whether to use antidepressant monotherapy due to the potential risk for inducing a treatment emergent affective switch. Pharmacists involved in management of patients with depressive mixed episodes can provide valuable input to the healthcare team by understanding available data as well as how to best manage this patient population. This program will improve pharmacists’ knowledge of the mixed features specifier, depressive mixed states presentation including common differential diagnoses, as well as inform pharmacists on evidence based treatment options for these patients.

Specific objectives include:

  • Review the rationale for developing the “mixed features” specifier in DSM-5.
  • Recognize presentations of mixed depressive episodes and common differential diagnoses.
  • Distinguish between evidence based treatment options for mixed depressive episodes with antipsychotics, mood stabilizers, and antidepressants, including antidepressant monotherapy.
  • Develop a treatment plan for a patient with a depressive episode with mixed features based on a patient case.

We are thrilled to have Michael Thase, MD guide us through this session. Dr. Thase joined the faculty of the Perelman School of Medicine at the University of Pennsylvania in 2007 as Professor of Psychiatry after more than 27 years at the University of Pittsburgh Medical Center and the Western Psychiatric Institute and Clinic. His research, which has been continuously funded by the Institutes of the NIH for nearly 30 years, focuses on the assessment and treatment of mood disorders, including studies of the differential therapeutics of both depression and bipolar affective disorder. A 1979 graduate of the Ohio State University College of Medicine, Dr. Thase is a Distinguished Fellow of the American Psychiatric Association, a Founding Fellow of the Academy of Cognitive Therapy, a member of the Board of Directors of the American Society of Clinical Psychopharmacology, and Vice Chairman of the Scientific Advisory Board of the National Depression and Bipolar Support Alliance. He has been elected to the membership of the American College of Psychiatrists and the American College of Neuropsychopharmacology. Dr. Thase has authored or co-authored more than 500 scientific articles and book chapters, as well as 15 books.

Return to The AAPP Perspective issue main page.< Previous Article  Next Article >